Asemblis is a Swiss TechBio company developing scalable, human-relevant in vitro models for obesity and metabolic disorders. The company partners with industry and research organizations to support translational R&D and decision-making in drug development
Cooperation possibilities
Our solution is currently in early development and is being advanced in collaboration with the Zurich University of Applied Sciences (ZHAW). At this stage, we are actively engaging with CROs and pharma partners to explore feasibility studies and pilot projects.
- https://asemblis.com/
- Send an email
- Caio Valeriano, CEO
Some insights
Asemblis supports better drug development by enabling more human-relevant research models. This helps improve decision-making, reduce reliance on animal testing, and accelerate the development of safer and more effective treatments.
We are proud to build a science-driven company that works closely with academic and industry partners to improve how drugs are developed, while promoting more human-relevant and ethical research practices.
We see companies and institutions advancing translational research, ethical innovation, and strong industry-academia collaboration as role models, particularly those helping translate science into better, more predictive drug development.
Our key strength is a senior, execution-oriented team with more than 25 years of combined experience across management, science, and international sales. As we grow, we aim to add strengths in technical (bioengineer), data analysis, and product management to support scale and industry adoption.
My wife would say I work on a product that help researchers develop better medicines. It’s still a bit technical, but she knows it’s about improving how drugs are tested and developed.
Support for easier access to CROs and pharma partners for early collaboration, feasibility studies, and pilot projects would be most valuable to us at this stage to accelerate validation and market adoption.
We would like to connect with pharma and biotech companies, CROs, academic groups, and innovation partners interested in early collaboration, feasibility studies, and translational research.
